"The big Oil Companies are not dropping their price at the pump commensurate with the sharply lower prices they are paying for Oil. Those prices are dropping like a rock!," Trump wrote in a Truth Social post. "In other words, customers are being "gouged." I have instructed the DOJ to immediately start looking into this. Gasoline prices better start going down a lot faster than what I'm seeing!," he added. Karen Young, a senior research scholar at the Columbia University Center on Global Energy Policy, descr ...

中钢国际工程技术股份有限公司投资者关系活动记录表 编号：2026-5 投资者关系 活动类别 ☐ 特定对象调研 分析师会议 ☐ 媒体采访 ☐ 业绩说明会 ☐ 新闻发布会 ☐ 路演活动 ☐ 现场参观 ☐ 其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 西部证券、金铂资产、诚旸投资、华创证券 时间 2026年6月23日 15:30-16:30 地点 北京 上市公司接待 人员姓名 董秘 袁陆生 董办 戚欣 投资者关系 活动主要内 容介绍 公司近期经营情况，主要交流内容附后。 交流内容未涉及公司内幕信息。 关于本次活 动是否涉及 应披露重大 信息的说明 本次活动不涉及未公开披露的重大信息。 附件清单（如有）投资者关系活动记录 日期 2026年6月23日 中钢国际工程技术股份有限公司 证券代码：000928 证券简称：中钢国际 答：公司2025年新签埃及短流程钢厂、阿曼直接还原铁、沙特无缝钢管等项 目，各个项目均在稳健推进中。目前，全球政治经济环境复杂变化，公司将全面 强化国际竞争力与可持续发展能力，坚持"巩固存量、拓展增量、优化结构"并 重，在稳定传统优势市场的基础上，加快市场多元化布局，进一步增强抗周期能 ...

评级与目标价调整 - 大和将吉利汽车投资评级由“持有”上调至“买入” [1][2] - 目标价由23.7港元上调至27港元，升幅为13.9% [1][2] 核心增长驱动力 - 高端品牌极氪（Zeekr）销售势头强劲，推动公司整体品牌向高端化升级 [1][2] - 海外市场持续扩张，预计将成为公司2026至2030年的核心增长动力 [1][2] - “一个吉利”策略带来集团内部协同效应，有望推动公司盈利持续增长 [1][2] 近期表现与市场认可 - 吉利汽车今年首5个月销售表现强劲 [1][2] - 极氪品牌销量占集团总销量的比例已升至12% [1][2] - 订单结构反映消费者对公司高端化策略的认可，有助于提升整体品牌形象 [1][2] 盈利预测调整 - 将2026至2028年销量预测上调1%至2%，以反映海外扩张及极氪9X的强劲订单势头 [1][2] - 将2026至2028年平均售价预测上调5%至6% [1][2] - 将2026至2028年毛利率预测上调0.3个百分点 [1][2] - 整体将2026至2028年收入预测上调6%至8% [1][2] - 将2026至2028年净利润预测上调12%至16% [1][2]

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Shah's experience growing a business in India is a significant part of his lure for Cox and Meta Chief Executive Officer Mark Zuckerberg, with Zuckerberg lauding his "builder mentality." Over the three-month hiring process that involved multiple trips for Shah to Meta's headquarters in California, including dinner at Zuckerberg's house, Cox developed a keen sense that Meta would benefit from someone who lives with WhatsApp in a way that few in the US can fully appreciate. Meta Platforms Inc.'s decision to h ...

WISeKey and Its Subsidiary WISeSat.Space Corp. Announce Filing of Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission Canton of Zug, Switzerland— June 24, 2026 — WISeKey International Holding Ltd. ("WISeKey") (SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity and IoT, and its subsidiary WISeSat.Space Corp. ("WISeSat") today announced the filing of a registration statement on Form F-4 with the U.S. Securities and Exchange Commission ("SEC") on May 29 ...

Maxim Group LLC is acting as exclusive financial advisor to WISeKey in connection with the business combination. Ellenoff Grossman & Schole LLP is acting as legal advisor to WISeSat and Pubco. Loeb & Loeb LLP is acting as legal advisor to CAC. Important Information about the Proposed Business Combination and where to Find it WISeKey and Its Subsidiary WISeSat.Space Corp. Announce Filing of Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission Canton of Zug, Switzerland— June 24 ...

港股创新药板块动态与政策环境 - 港股盘初集体反弹，港股通创新药ETF汇添富（159570）涨超3%，盘中成交额快速突破4亿元 [1] - 高层调研强调打造生物医药新兴支柱产业，培育发展脑机接口未来产业，加快高水平科技自立自强 [1] - 国家药监局报告显示，2025年中国临床试验总量首次突破5000项，创历史新高，其中新药临床试验2997项，占比57.5%，同比增长18% [1] 行业研发进展与产品获批 - 正大天晴申报的注射用维特柯妥拜单抗（LM-302）上市申请获受理，适用于CLDN18.2阳性胃/胃食管交界处腺癌患者，此前已被纳入优先审评 [1] - 维特柯妥拜单抗是靶向CLDN18.2的抗体偶联药物（ADC），中国生物制药宣布将以约5亿美元净代价100%收购其研发公司礼新医药 [2] - 百利天恒1类新药「伦康依隆妥单抗」在国内获批上市，用于治疗鼻咽癌，该药是全球首创且唯一进入III期临床的EGFR×HER3双抗ADC，也是全球首个获批上市的双抗ADC新药 [2] - 荣昌生物宣布，泰它西普（RC18）治疗干燥综合征和IgA肾病的两项新适应症获NMPA批准上市，标志着干燥综合征领域迎来全球首个获批的生物制剂 [5] 市场表现与成分股情况 - 港股通创新药ETF汇添富(159570)标的指数热门成分股多数上涨：百济神州涨超3%，信达生物涨超2%，康方生物、中国生物制药涨超1% [3] - 该ETF标的指数100%布局创新药，截至6月3日，前十大成分股权重超73% [9] 券商观点与行业分析 - 中泰证券认为，创新药板块受上市公司回购、估值历史底部、创新政策持续加码三重支撑，7-8月中报业绩窗口期，具备超预期临床/BD数据的龙头将走出独立修复行情 [4] - 西南证券指出，创新药板块处于估值底部，利好频频，有望底部反转，并提及云顶新耀、信达生物、海思科分别与跨国药企达成高额合作，涉及里程碑付款高达10.3亿美元、105亿美元和30.5亿美元 [5][6] - 东吴证券表示，医保九号文强调创新药将获得相应高回报，文件提到要优化创新药首发价格机制，区分药品创新程度，差异化定价支持，并拓宽创新药支付渠道 [7] - 湘财证券认为创新药仍是医药行业核心增量，国内医保支出持续向创新药倾斜，叠加全链条扶持政策落地，为板块提供坚实支撑，2026年以来指数调整主要受市场风格偏好切换影响 [8] 产业合作与数据更新 - 云顶新耀将BTK抑制剂EVER001授权给Travere Therapeutics，获得1.125亿美元首付款，并有资格获得高达10.3亿美元的里程碑付款 [6] - 信达生物、海思科分别与辉瑞、礼来等跨国药企达成105亿和30.5亿美元的合作 [6] - 2026年陆家嘴论坛指出，支持生物制造等“硬科技”企业在科创板上市，上交所修订相关暂行规定，在生物医药领域新增“脑机接口、生物药品”等内容 [7] - 2026年5月社零数据显示，中西药品类1-5月累计同比增长3.1%，5月单月同比增长4.0%，显示二季度数据明显好转 [7]

I have a B.Tech degree in Mechanical Engineering from a top school in India. For nearly twenty five years, I have worked in the oil and gas sector, primarily in the Middle East. I work at the intersection of engineering, operations, and project management in an industry that does not forgive mistakes - so I have learned to be efficient, careful, and disciplined. These traits inform my investment strategy. For much of my professional career, I have maintained a serious and sustained interest in the U.S. equi ...

Albuquerque, New Mexico--(Newsfile Corp. - June 24, 2026) - Travel Smart Travel Fast today announced updated 2026 guidance for travelers preparing for international trips as more governments move border entry requirements to online pre-arrival authorization systems. The update focuses on Europe's Entry/Exit System (EES), the upcoming European Travel Information and Authorisation System (ETIAS), and other electronic travel authorization programs that are becoming a regular part of cross-border travel plannin ...